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Using the Swedish Family-Cancer Database, among a total of 1030806 women followed from 1993 through 2004, invasive and
borderline epithelial ovarian cancer was identified in 3306 and 822 women respectively, with data on family history, reproductive
variables, residential region and socioeconomic status. Relative risks and population-attributable fractions (PAFs) were estimated by
Poisson regression. The overall PAFs of invasive epithelial ovarian cancer for family history and for reproductive factors were 2.6 and
22.3%, respectively, for serous/seropapillary cystadenocarcinoma (3.0 and 19.1%), endometrioid carcinoma (2.6 and 26.6%),
mucinous cystadenocarcinoma (0.5 and 23.9%) and clear-cell carcinoma (2.6 and 73.9%). The corresponding PAFs of borderline
tumours due to family history were lower, but higher due to reproductive factors. Family history, low parity and young age at first
birth were associated with elevated risks. The risks for women with a family history were among the highest, but these women
accounted for the smallest proportion of the cases, giving the lowest PAFs.
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Most cases of invasive epithelial ovarian cancer (EOC), which
constitute 80–90% of all ovarian malignancies, are detected at an
advanced stage after age 40 years (Holschneider and Berek, 2000).
Invasive EOC can be further subdivided into serous (75–80%),
mucinous (10%), endometrioid (10%), clear-cell and other
morphological types (Holschneider and Berek, 2000). Most studies
suggest that apart from mucinous tumours, all the major
morphologies tend to share a common aetiology (Whiteman
et al, 2000; Purdie et al, 2003; Tung et al, 2003; Parazzini et al,
2004; Chiaffarino et al, 2007). There is strong evidence that
multiparity and oral contraceptive use are protective factors
(Adami et al, 1994; La Vecchia, 2006), as well as tubal ligation and
hysterectomy (Green et al, 1997; Kjaer et al, 2004). Breastfeeding
has shown a weaker inverse association, but not all studies have
observed this (Riman et al, 2002; Chiaffarino et al, 2005).
Additional risk factors include nulliparity and infertility (Banks
et al, 1997), but the findings on the use of hormone replacement
therapy are inconsistent (Riman et al, 2002; Kurian et al, 2005).
Another well-established risk factor is a family history of EOC
(Hemminki and Granstrom, 2003). The strongest association has
been observed for the non-mucinous morphologies, whereas in
one study the mucinous type was not associated with a family
history (Purdie et al, 2001).
We use here the year 2006 update of the nation-wide Swedish
Family-Cancer Database to determine relative risks (RRs) and
population-attributable fractions (PAFs) of invasive and border-
line EOC for reproductive, familial, socioeconomic and residential
factors.
MATERIALS AND METHODS
Statistics Sweden created a family database, ‘Second Generation
Register’ in 1995. After a few expansions, it covered offspring born
after 1931 with their parents, renamed ‘Multigeneration Register’,
to indicate that the number of generations was more than two.
We have linked this Register to the Swedish Cancer Registry
(1958–2004) to make the Family-Cancer Database (MigMed2) in
year 2006 for the seventh time. This now contains data on all
immigrants, whereas previous versions only included those who
had had children in Sweden. All data are organised in child–
mother–father triplets; the parents have been registered at the
time of birth of the child, allowing tracking of biological parents.
The database includes all persons resident in Sweden after 1931
with their biological parents, totalling over 11.5 million indivi-
duals. The present study included Swedish-born as well as
immigrant women born between years 1932 and 1953, that is,
those whose minimal age at the beginning of the follow-up ranged
from 40 to 61 years.
The completeness of cancer registration in the 1970s has been
estimated to be over 95%, and is now considered close to 100%.
The percentage of cytologically or histologically verified cases
of EOC has been close to 100% (Center for Epidemiology, 2007).
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of cases (Center for Epidemiology, 2007). A four-digit diagnostic
code according to the International Classification of Diseases,
seventh revision was combined with morphology codes according
to the International Classification of Diseases for Oncology, World
Health Organization (WHO) and the Systematized Nomenclature
of Medicine (SNOMED) used since 1993. The ICD-7 code 175 was
used to identify EOC cases, and a Swedish version of SNOMED was
used to classify the morphological subtypes.
Follow-up was started at immigration or January 1, 1993,
whichever came latest, and terminated on diagnosis of first cancer,
death, emigration or the closing date of the study, December 31,
2004. A Poisson regression analysis was performed to model
overall EOC incidence using the following variables: age at
diagnosis (5-year bands), family history of invasive EOC, parity,
age at first child birth, socioeconomic status and residential area
(Clayton and Schifflers, 1987a,b). A separate Poisson regression
analysis was also performed for each morphology: serous,
endometrioid, mucinous and clear cell. Epithelial borderline
tumours were considered as a whole. Relative risks and confidence
intervals (95% CIs) were calculated using Poisson regression.
Although not shown in the results, age at diagnosis was always
included in the model.
The PAF is the proportion of disease cases in a population that
is attributable to a particular exposure or cause. Using the relevant
variables from the Poisson regression models, individual PAFs
due to each of the variables were calculated on the basis of RRs
generated by new Poisson regression models with the variables
classified dichotomously (exposed/unexposed). The population
belonging to the lowest level of the variables in the initial Poisson
regression models was defined as unexposed and the other levels
were aggregated into the exposed group. The population-
attributable fraction was calculated according to the formula
((RR 1)/RR) the proportion of cases in the exposed population,
where RR was the risk in the exposed population (Miettinen, 1974).
For joint PAFs, defining the unexposed population as those
unexposed to all risk factors simultaneously, we used the formula
((incall incref)/incall) 100, where incall denotes the overall
incidence and incref denotes that in the unexposed population.
The incidence was age-standardised according to the Swedish
census of year 2000. Confidence intervals for PAFs were estimated
by bootstrapping with 1000 simulations (Greenland, 2004).
RESULTS
A total of 1030806 women, with 11091139 person-years at risk
were included, were followed from 1993 through 2004. Invasive
and borderline EOC were identified in 3306 and 822 women,
respectively, with data on family history, reproductive variables,
socioeconomic status and residential region. Variables included in
the Poisson regression models were age at diagnosis, family
history, parity, age at first child birth, all of which had a significant
or borderline significant effect on the risk of EOC; additionally, the
effect of socioeconomic status and residential area were tested. The
result of the Poisson analysis is shown in Table 1. A family history
through a mother proband increased the risk of overall invasive
EOC to 2.54, and through a sister to 2.76 relative to women with no
family history. Nulliparity showed the highest RR, with an overall
RR of 2.12 relative to those who had at least three children. Low
parity increased RRs, as well as younger ages at first childbirth.
There were small or no risks associated with residential region and
socioeconomic status in the overall invasive EOC, but, for
completeness, these variables were still included in the model
although their exclusion did not alter risks associated with the
other variables.
The invasive cases comprised 45% serous/seropapillary cysta-
deno, 15% endometrioid, 8% mucinous cystadeno and 5% clear-
cell cystadenocarcinomas. Poisson regression analysis for these are
being shown in Table 1. As in the overall EOC, these types showed
positive associations with family history through a mother or sister
proband (serous: 2.93 and 2.57, respectively; endometrioid: 2.22
and 3.65, respectively; clear cell: 2.63 and 2.40, respectively), except
in mucinous cystadenocarcinoma of which there were very few
cases. There was a clear trend for decreasing RRs with increasing
parity in all morphologies, except mucinous tumours, which
showed no trend. A similar trend for decreasing RRs with
increasing age at first child birth was observed in the serous
group, but with clear cell morphology this was reversed. No clear
trend was observed for age at first child birth in the mucinous and
endometrioid morphologies. Nulliparity showed the highest RRs in
clear-cell carcinoma, with an overall significant RR of 6.73 relative
to those who had at least three children, whereas serous/
seropapillary and endometrioid cystadenocarcinomas had signifi-
cant RRs of 1.86 and 2.77 respectively. In general, low parity had
the highest impact on clear cell carcinoma. Unlike the other
morphologies, mucinous cystadenocarcinoma was not positively
associated with nulliparity. Residential region had significant or
borderline significant moderately elevated risks, ranging from
1.11 to 1.35, with the reference groups north or south in all
morphologies except from mucinous. The highest RRs were found
in the clear cell morphology. There was a negative, but
insignificant, association with high socioeconomic status and
endometrioid, mucinous and clear-cell tumours as opposed to the
serous morphology where the results were harder to interpret as all
the defined socioeconomic groups had increased but very similar
RRs.
The corresponding result for all epithelial borderline tumours is
shown in Table 1. Here, family history refers to family history of
invasive disease. The association with a mother history was weaker
compared with the corresponding invasive analysis, but these RRs
were not significant. A trend for decreasing RRs with increasing
parity and also a similar trend for decreasing RRs with increasing
age at first child birth was observed. Low parity showed higher RRs
compared with the corresponding invasive model. Residential
region had no elevated risk, but there was a negative association
with high socioeconomic status.
For calculation of PAF, the individual variables in Table 1
were classified dichotomously into one group, the reference or
unexposed group, and into the other, the exposed group (Table 2).
As nulliparous women have no age at first birth, parity and age at
first birth were merged into one variable. In order to calculate a
joint PAF, all the unexposed groups of the individual variables
were combined simultaneously to form the joint reference group.
Socioeconomic status was excluded in this analysis due to the
limited number of cases in the joint reference group, but this did
not alter the other individual PAFs. The joint PAFs in all invasive
EOC and mucinous carcinoma were similar, 26.5 and 29.6%,
respectively, which was equal to the individual PAFs due to
reproductive factors. Serous/seropapillary cystadeno and endome-
trioid carcinomas had large joint PAFs of 49.4 and 48.5%,
respectively, explaining half of all cases. Clear-cell carcinoma
showed a notable large PAF of 66.0%, most likely due to only one
case in the joint reference group. The joint PAF in serous/
seropapillary cystadeno and endometrioid carcinomas exceeded
the sum of the individual PAFs, whereas in all EOC, mucinous
cystadeno and clear-cell carcinomas the corresponding sum
exceeded the joint PAF, perhaps because some risk factors cancel
each other out. The corresponding joint PAF for the borderline
tumours was equal.
DISCUSSION
The major strength of this study is the large number of women
from the nation-wide Swedish Family-Cancer Database and the
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All epithelial
Serous/seropapillary
cystadenocarcinoma
Endometrioid
carcinoma
Mucinous
cystadenocarcinoma Clear-cell carcinoma
All epithelial borderline
malignancy
Variable CasesRR (95% CI) Cases RR (95% CI) Cases RR (95% CI) Cases RR (95% CI) Cases RR (95% CI) Cases RR (95% CI)
Family history
Family history 140 2.60(2.20–3.08) 68 2.83 (2.22–3.61) 21 2.61 (1.68–4.03) 6 1.32 (0.59–2.98) 8 2.57 (1.27–5.22) 21 1.51 (0.98–2.33)
Mother 99 2.54(2.08–3.11) 51 2.93 (2.22–3.88) 13 2.22 (1.28–3.85) 3 0.92 (0.29–2.86) 6 2.63 (1.17–5.94) 12 1.18 (0.67–2.09)
Sister 41 2.76(2.03–3.76) 17 2.57 (1.59–4.14) 8 3.65 (1.81–7.34) 3 2.39 (0.77–7.46) 2 2.40 (0.60–9.69) 9 2.38 (1.23–4.59)
No history 3166 1 1419 1 472 1 266 1 182 1 801 1
Parity
0 586 2.12(1.81–2.48) 236 1.86 (1.47–2.37) 107 2.77 (1.85–4.16) 28 0.97 (0.54–1.72) 59 6.73(3.38–13.42) 114 2.09 (1.50–2.92)
1 643 1.60(1.43–1.79) 272 1.46 (1.24–1.73) 100 1.75 (1.31–2.33) 58 1.46 (1.01–2.10) 43 3.34 (1.97–5.67) 169 1.96 (1.57–2.45)
2 1329 1.21(1.10–1.32) 630 1.23 (1.07–1.40) 180 1.16 (0.90–1.48) 113 1.05 (0.78–1.42) 65 1.85 (1.14–3.01) 371 1.49 (1.24–1.80)
3+ 748 1 349 1 106 1 73 1 23 1 168 1
Age at first birth
13–20 637 1.13(0.98–1.30) 293 1.17 (0.95–1.43) 99 1.31 (0.91–1.88) 58 1.03 (0.65–1.64) 25 1.03 (0.55–1.93) 176 1.48 (1.12–1.95)
21–24 925 1.08(0.95–1.23) 444 1.15 (0.95–1.39) 119 1.04 (0.74–1.47) 79 0.96 (0.63–1.48) 40 1.04 (0.59–1.84) 246 1.30 (1.00–1.69)
25–29 814 1.06(0.93–1.20) 361 1.02 (0.84–1.24) 119 1.15 (0.82–1.61) 75 1.05 (0.69–1.60) 47 1.28 (0.74–2.21) 205 1.18 (0.91–1.54)
30+ 344 1 153 1 49 1 32 1 19 1 81 1
Socioeconomic status
Manual worker 1246 1.10(1.01–1.19) 557 1.28 (1.06–1.56) 171 1.06 (0.78–1.42) 102 1.17 (0.77–1.78) 62 1.19 (0.72–1.95) 311 1.35 (1.05–1.73)
Professional 415 1.03(0.92–1.15) 193 1.29 (1.03–1.62) 61 1 29 1 22 1 80 1
Other 350 1.02(0.90–1.15) 129 1 63 1.24 (0.87–1.77) 37 1.49 (0.91–2.43) 29 1.64 (0.94–2.86) 85 1.29 (0.95–1.75)
Blue collar 1295 1 608 1.26 (1.04–1.53) 198 1.02 (0.76–1.36) 104 1.09 (0.72–1.64) 77 1.11 (0.69–1.79) 346 1.30 (1.02–1.66)
Residential region
Big city 1189 1.09(0.99–1.20) 543 1.23 (1.06–1.42) 200 1.25 (1.02–1.53) 82 1 76 1.35 (0.89–2.05) 283 1
South 1449 1.11(1.01–1.21) 673 1.27 (1.10–1.46) 187 1 124 1.23 (0.93–1.63) 82 1.31 (0.87–1.97) 361 1.03 (0.88–1.21)
North 668 1 271 1 106 1.11 (0.88–1.41) 66 1.29 (0.93–1.79) 32 1 178 1.01 (0.83–1.21)
All 3306 1487 493 272 190 822
Abbreviations: CI¼confidence interval: RR¼relative risk. Period of follow-up, 1993–2004.
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EpidemiologyTable 2 PAFs in EOC
Invasive Borderline
Morphology/variable Cases RR (95% CI) Prop (%) PAF (%) (95% CI) Morphology/variable Cases RR (95% CI) Prop (%) PAF (%) (95% CI)
All epithelial invasive All epithelial borderline malignancy
Family history Family history
Family history 140 2.60 (2.20–3.08) 4.23 2.6 (2.4–2.8) Family history 21 1.51 (0.98–2.33) 2.55 0.9 (0.5–1.1)
No history 3166 1 95.77 No history 801 1 97.45
Parity and age at first birth Parity and age at first birth
Other 2830 1.35 (1.23–1.49) 85.60 22.3 (20.3–24.0) Other 729 1.76 (1.42–2.18) 88.69 38.3 (34.8–41.5)
3+: 21+ 476 1 14.40 3+: 21+ 93 1 11.31
Residential region Residential region
Other 2638 1.10 (1.01–1.20) 79.79 7.2 (5.3–8.9) Other 539 1.04 (0.90–1.20) 65.57 2.7 (0.3–5.3)
North 668 1 20.21 Big city 283 1 34.43
All All
Other 3208 97.04 26.5 (22.0–34.5) Other 787 95.74 24.8 (17.9–33.1)
All combined 98 2.96 All combined 35 4.26
Serous/seropapillary cystadenocarcinoma
Family history
Family history 68 2.83 (2.22–3.61) 4.57 3.0 (2.6–3.2)
No history 1419 1 95.43
Parity and age at first birth
Other 1263 1.29 (1.12–1.49) 84.94 19.1 (16.3–21.7)
3+: 21+ 224 1 15.06
Residential region
Other 1216 1.25 (1.10–1.43) 81.78 16.5 (13.9–19.3)
North 271 1 18.22
All
Other 1454 97.78 49.4 (44.6–55.0)
All combined 33 2.22
Endometrioid carcinoma
Family history
Family history 21 2.61 (1.68–4.04) 4.26 2.6 (2.1–3.1)
No history 472 1 95.74
Parity and age at first birth
Other 427 1.44 (1.11–1.87) 86.61 26.6 (21.8–31.3)
3+: 21+ 66 1 13.39
Residential region
Other 306 1.23 (1.02–1.47) 62.07 11.5 (8.7–14.3)
North 187 1 37.93
All
Other 469 95.13 48.5 (43.0–55.3)
All combined 24 4.87
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Invasive Borderline
Morphology/variable Cases RR (95% CI) Prop (%) PAF (%) (95% CI) Morphology/variable Cases RR (95% CI) Prop (%) PAF (%) (95% CI)
Mucinous cystadenocarcinoma
Family history
Family history 6 1.33 (0.59–2.98) 2.21 0.5  (0.1–0.9)
No history 266 1 97.79
Parity and age at first birth
Other 240 1.37 (0.95–1.98) 88.24 23.9 (17.7–31.3)
2: 21–24 32 1 11.76
Residential region
Other 190 1.27 (0.98–1.64) 69.85 14.7 (10.4–18.9)
Big city 82 1 30.15
All
Other 262 96.32 29.6 (20.3–45.7)
All combined 10 3.68
Clear cell carcinoma
Family history
Family history 8 2.57 (1.27–5.21) 4.21 2.6 (1.8–3.2)
No history 182 1 95.79
Parity and age at first birth
Other 185 4.15 (1.71–10.09) 97.37 73.9 (70.2–82.4)
3+: 13–20 5 1 2.63
Residential region
Other 158 1.35 (0.92–1.97) 83.16 21.3 (15.2–28.8)
North 32 1 16.84
All
Other 189 99.47 66.0 (58.4–100)
All combined 1 0.53
Abbreviations: CI¼confidence interval; EOC¼epithelial ovarian cancer; PAF¼population-attributable fraction; RR¼relative risk. Period of follow-up, 1993–2004.
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Epidemiologyregistered and unbiased information on all variables. One
limitation of the data source is the lack of information on known
or potential risk/protective factors such as oral contraceptive use
(Franceschi et al, 1991; Kumle et al, 2004), hormone replacement
therapy (Mills et al, 2005; Danforth et al, 2007), breast feeding
(Riman et al, 2002; Chiaffarino et al, 2005), menstrual history
(Zografos et al, 2004; Riman et al, 2004b), dietary habits (Bosetti
et al, 2001; Larsson et al, 2004) and obesity (Riman et al, 2004a;
Olsen et al, 2007).
In this study family history of disease, low parity and young age
at first birth increased the risk of both non-mucinous invasive and
borderline EOC. Due to very few cases, no clear conclusions could
be drawn regarding the risk of family history in the mucinous
morphology. Low socioeconomic status seemed to be associated
with borderline tumours as opposed to residential region.
Population-attributable fraction is the proportion of disease
cases in a population that is attributable to a particular exposure or
‘the fraction of all cases (exposed and unexposed) that would not
have occurred if exposure had not occurred (Miettinen, 1974;
Rothman and Greenland, 1998; dos Santos Silva, 1999)’. Assuming
exposure to be causal and removable, PAF could be used to
estimate the potential impact of public health interventions. In this
study however, exposures are not removable and PAF is used as an
aetiological measure. The joint PAF of more than one exposure can
analogously be defined as the fraction of cases that would not have
occurred if all the exposures were avoided. Large PAFs indicate
that a large proportion of the aetiology is understood at the level of
the defined variable. Since PAF here is defined as the product of
the expression ((RR 1)/RR) and the proportion of cases in the
exposed population, large PAFs can only result from a high RR and
relatively common exposure or from a moderate RR and common
exposure.
No study has previously estimated morphology-specific PAFs
for EOC, and few studies have estimated general PAFs (Parazzini
et al, 2000; Hemminki and Granstrom, 2003). Our findings showed
similar PAFs throughout all morphologies, with the exception of
clear-cell carcinoma, regarding family history and reproductive
factors. In these morphologies, family history accounted for the
smallest PAFs (between 0.5 and 3.0%) due to the small proportion
of exposed women, although these women had the highest RRs. A
previous study estimated PAF due to family history of breast or
ovarian cancer to 4% (Parazzini et al, 2000). The broad definition
of exposure due to parity and age at first child birth resulted in
very large (more than 80%) exposed groups, with resulting PAFs
between 19.1 and 26.6%, although the corresponding RRs were
low. An exception to this could be observed in clear-cell carcinoma
where a high RR and an exceptionally small exposed group
resulted in a reproduction-related PAF of 73.9%. The moderate to
high PAFs due to being a resident in high-risk geographical areas
seen in the specific morphologies are a possible result of potential
risk/protective factors correlating with these areas, such as
different use of oral contraceptives, hormone replacement therapy,
obesity and dietary habits. These results could also be explained by
different pathology classification criteria across medical regions.
In two of the models, the serous/seropapillary and endometrioid
morphologies, the sum of the individual PAFs was less than the
corresponding joint PAF. According to these models, PAFs of 49.4
and 48.5% suggest that the three variables explain half of all cases.
For specific morphological types, the interpretation is not clear as
the residential region probably hides other factors contributing to
the disease.
Also in the borderline model, family history accounted for the
smallest individual PAF and reproductive factors for the highest
PAFs. The borderline PAF was smaller than the corresponding
invasive one due to family history, but larger due to reproductive
factors, whereas the joint invasive and borderline PAFs were equal.
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